Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab with Concurrent Chemoradiation for Locally Advanced NSCLC
NCT02621398Phase 1Completed
- Sponsor
- Rutgers University
- Start
- Aug 2016
- Primary completion
- Oct 2019
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by Rutgers University. Primary endpoint: Maximum Tolerated Dose and Dose Limiting Toxicity up to 30 days. Started Aug 2016; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02621398.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02621398.